Summary:
This will be a first time in human study in sickle cell diseases (SCD) participants. The study is planned to evaluate the safety, tolerability, and pharmacokinetics of GSK4172239D.
The study will be composed of 3 periods for all participants (Screening, Treatment, and Follow up).
This study will be a single dose, dose-escalation study.
Inclusion criteria:
- Participants diagnosed with SCD not taking medication which increases gamma-globin (fetal hemoglobin).
- Participants with SCD who have failed or not tolerated one or more approved therapies for SCD
- Body weight greater than (>) 50 kilogram (kg).
- For male participants: Refrain from donating sperm plus either be abstinent from heterosexual intercourse as their preferred and usual lifestyle and agree to remain abstinent. OR agree to use a male condom with female partner
- For female participants: Female participants are eligible to participate if they are a woman of non-childbearing potential (WONCBP).
- Capable of giving informed consent.
Qualified Participants May Receive:
Great care and close monitorting